Pediatric Atopic Dermatitis Management in 2026: Topical, Systemic, and Emerging Therapies

Conclusions

• The presentation concludes that many children with moderate to severe atopic dermatitis are undertreated initially and should first receive optimized topical therapy before moving to systemic treatment.
• It suggests that systemic steroids should almost never be used in children, while older immunosuppressants such as cyclosporine and methotrexate remain fallback options when newer agents are unavailable or ineffective.
• The talk argues that pathogenesis-based biologics, especially dupilumab, have transformed pediatric atopic dermatitis care by providing strong efficacy with an excellent long-term safety profile.
• It concludes that dupilumab can be used from 6 months of age, does not require routine laboratory monitoring, and can often be continued long enough to allow periods of remission or treatment breaks.
• The presentation emphasizes that dupilumab reduces skin infections, may improve growth and sleep, and may lessen the broader inflammatory burden of atopic disease.
• It suggests that treating pediatric atopic dermatitis may also improve associated allergic conditions such as asthma, rhinitis, and food allergy, although the clinical meaning of biomarker changes like reduced IgE is still uncertain.
• The speaker concludes that current biologics appear reassuring even in very young children, with no clear signal of harm to the developing immune system or live-vaccine responses so far, but that longer follow-up is still needed.
• It notes that IL-13 inhibitors such as tralokinumab and lebrikizumab are viable alternatives in adolescents and can maintain benefit with less frequent dosing.
• The presentation concludes that JAK inhibitors offer rapid itch relief and oral convenience in older children and adolescents, but safety concerns and boxed warnings limit broader pediatric confidence for now.
• Overall, the talk concludes that pediatric atopic dermatitis care is moving toward safer, targeted, longer-acting therapies, with the future likely to include extended-interval antibodies, bispecifics, OX40L blockade, and oral STAT6-targeted drugs.